Therapy of superficial bladder carcinomas

Area of Science:

• Urology
• Oncology
• Cancer Research

Background:

• Superficial bladder carcinoma treatment strategies are informed by risk stratification based on tumor grade and stage.
• Standard initial management involves transurethral resection (TUR).

Purpose of the Study:

• To outline current evidence-based treatment guidelines for superficial bladder cancer.
• To define the role of adjuvant intravesical therapies in managing different risk groups.

Main Methods:

• Review of large randomized trials on superficial bladder carcinoma.
• Stratification of tumors into risk groups (Ta G1-2, T1 G1-2, Tis/T1 G3).

Main Results:

• Primary Ta G1-2 tumors do not require adjuvant therapy post-TUR due to low recurrence and progression risk.
• Intravesical mitomycin C or adriamycin can decrease recurrence rates by up to 15% in recurrent Ta or T1 G1-2 tumors.
• Intravesical BCG is indicated for high-grade tumors (Tis/T1 G3) and as adjuvant therapy.

Conclusions:

• Treatment decisions for superficial bladder cancer should be risk-stratified.
• Adjuvant intravesical therapies, including mitomycin C, adriamycin, and BCG, play a crucial role in preventing recurrence and managing high-risk tumors.
• Radical cystectomy is reserved for patients who do not respond to initial treatments.